INmune Bio Management
Management criteria checks 3/4
INmune Bio's CEO is RJ Tesi, appointed in Sep 2015, has a tenure of 8.67 years. total yearly compensation is $1.69M, comprised of 29.5% salary and 70.5% bonuses, including company stock and options. directly owns 7.79% of the company’s shares, worth $18.22M. The average tenure of the management team and the board of directors is 8.6 years and 6.8 years respectively.
Key information
RJ Tesi
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 29.5% |
| CEO tenure | 8.7yrs |
| CEO ownership | 7.8% |
| Management average tenure | 8.6yrs |
| Board average tenure | 6.8yrs |
Recent management updates
Recent updates
Is INmune Bio (NASDAQ:INMB) Using Debt Sensibly?
Jan 19
Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way?
Sep 04Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?
May 12Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money
Jan 16Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money
Jul 11INmune Bio: Possibly The Once In A Lifetime Dip
May 25INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid Tumors
Apr 05Is INmune Bio (NASDAQ:INMB) A Risky Investment?
Mar 25Is INmune Bio (NASDAQ:INMB) Using Too Much Debt?
Dec 02INmune Bio A No-Brainer Investment
Oct 13INmune Bio: High-Risk High-Reward Alzheimer's Play
Aug 18Our Bullish Take On INmune Bio's Drug Pipeline
Aug 12INmune Bio: Underfollowed AD Player With Very Bullish August Momentum
Jul 13Companies Like INmune Bio (NASDAQ:INMB) Are In A Position To Invest In Growth
Jun 25INmune enters $15M credit facility to fund purchase of Xencor option
Jun 14INmune Bio (NASDAQ:INMB) Is In A Strong Position To Grow Its Business
Mar 01What Kind Of Investors Own Most Of INmune Bio, Inc. (NASDAQ:INMB)?
Jan 05
Here's Why We're Not Too Worried About INmune Bio's (NASDAQ:INMB) Cash Burn Situation
Dec 01INmune Bio EPS misses by $0.19
Nov 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$501k | -US$30m |
| Sep 30 2023 | n/a | n/a | -US$27m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$27m |
| Dec 31 2022 | US$1m | US$455k | -US$27m |
| Sep 30 2022 | n/a | n/a | -US$31m |
| Jun 30 2022 | n/a | n/a | -US$33m |
| Mar 31 2022 | n/a | n/a | -US$33m |
| Dec 31 2021 | US$3m | US$455k | -US$30m |
| Sep 30 2021 | n/a | n/a | -US$24m |
| Jun 30 2021 | n/a | n/a | -US$19m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$300k | US$300k | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$11m |
| Jun 30 2020 | n/a | n/a | -US$10m |
| Mar 31 2020 | n/a | n/a | -US$8m |
| Dec 31 2019 | US$1m | US$248k | -US$8m |
| Sep 30 2019 | n/a | n/a | -US$7m |
| Jun 30 2019 | n/a | n/a | -US$6m |
| Mar 31 2019 | n/a | n/a | -US$11m |
| Dec 31 2018 | US$3m | US$120k | -US$12m |
Compensation vs Market: RJ's total compensation ($USD1.69M) is about average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: RJ's compensation has increased whilst the company is unprofitable.
CEO
RJ Tesi (67 yo)
8.7yrs
Tenure
US$1,694,818
Compensation
Dr. Raymond Joseph Tesi, MD, also known as RJ, serves as Director at Bexion Pharmaceuticals, Inc. Dr. Tesi is the Co-Founder of INmuneBio Inc. and has been its Chief Medical Officer and Chairman and serves...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 8.7yrs | US$1.69m | 7.79% $ 18.2m | |
| CFO, Treasurer & Secretary | 8.7yrs | US$1.59m | 6.42% $ 15.0m | |
| Chief Scientific Officer & Chief Manufacturing Officer | 8.6yrs | US$150.24k | 7.65% $ 17.9m | |
| General Counsel | 5.3yrs | no data | no data |
8.6yrs
Average Tenure
60yo
Average Age
Experienced Management: INMB's management team is seasoned and experienced (8.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 8.7yrs | US$1.69m | 7.79% $ 18.2m | |
| Independent Director | 4.8yrs | US$301.66k | no data | |
| Independent Director | 4.5yrs | US$301.66k | no data | |
| Independent Director | 6.2yrs | US$301.66k | 0.34% $ 788.6k | |
| Independent Director | 7.7yrs | US$301.66k | 0.090% $ 210.7k | |
| Independent Director | 7.4yrs | US$301.26k | 0.42% $ 973.1k |
6.8yrs
Average Tenure
64.5yo
Average Age
Experienced Board: INMB's board of directors are considered experienced (6.8 years average tenure).